Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DKN-01 + Gemcitabine + Cisplatin in Advanced Biliary Tract Cancer
NCT02375880Phase 1Completed
- Sponsor
- Leap Therapeutics, Inc.
- Start
- Jun 2015
- Primary completion
- Jul 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of sirexatamab in biliary tract cancer (BTC) and gallbladder cancer (3 arms), sponsored by Leap Therapeutics, Inc. Primary endpoints: Maximum Tolerated Dose, Dose-Limiting Toxicities and 1 more. Started Jun 2015; status: completed.
02
Drugs
sirexatamab
03
Conditions
biliary tract cancer (BTC)gallbladder cancer
Beyond the preview
Go deeper on NCT02375880.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02375880.